This study is testing a new drug called SG2501 for people with blood cancers like lymphoma that have come back or don't respond to treatment. It's a phase Ia/Ib study, which means it's one of the first tests in humans to check if the drug is safe and how it works in the body. The study will occur in different places and will involve two phases to find the best dose.

In phase Ia, small groups will receive increasing doses to find the highest dose that doesn't cause bad side effects. Then, in phase Ib, more participants will get the drug at this dose to see if it's effective.

• The study is for adults 18 and older with specific types of blood cancer.
• Participants will have regular check-ups and tests to monitor their health.
• Participants must agree to use contraception and avoid pregnancy during the study.

This study is important for developing new treatments for cancer, but it also requires commitment and frequent visits to the clinic. Make sure you understand the risks and benefits before deciding to participate.